Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort
Resumen
Palabras clave
VIH; Terapia triple; Combinaciones de dos medicamentos
Citación recomendada
Teira R, Diaz-Cuervo H, Aragão F, Castaño M, Romero A, Roca B, et al. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort. Infect Dis Ther. 2022 Apr 11;11:1177-92.
Audiencia
Professionals
Usar este identificador para citar y/o enlazar este documento
https://hdl.handle.net/11351/7940Este elemento aparece en las siguientes colecciones
- HG - Articles científics [97]
- HVH - Articles científics [3024]
El ítem tiene asociados los siguientes ficheros de licencia: